The topic you requested could not be found.
Related topics are listed below.

Q108 – 112: Post-Infusion Therapy

Transplant Essential Data (TED) Manuals » 2450: Post-TED » Q108 – 112: Post-Infusion Therapy

!Malignant Diseases Only Only complete questions 108 – 112 if the HCT being reported was given to treat a malignant disease. If the HCT being reported was given to treat a non-malignant disease, leave questions 108-112 blank. FormsNet3SM should enable / disable this…

Q81 – 130: Acute Graft vs. Host Disease (GVHD)

Comprehensive Baseline & Follow-up Manuals » 2100: Post-Infusion Follow-Up » Q81 – 130: Acute Graft vs. Host Disease (GVHD)

*Autologous Transplants If this was an autologous infusion or syngeneic, continue with the Infection Prophylaxis section. The graft-versus-host disease sections should only be completed if an allogeneic donor was used. !Acute GVHD Prophylaxis Acute GVHD prophylaxis…

Q95-130: Disease Status at the Time of Evaluation for This Reporting Period

Comprehensive Disease-Specific Manuals » 2011/2111: Acute Lymphoblastic Leukemia (ALL) » 2111: ALL Post-Infusion » Q95-130: Disease Status at the Time of Evaluation for This Reporting Period

Question 95: Does the current disease status reflect the disease detected in this reporting period section (as captured in questions 48-80), without subsequent therapy? This section of the form is intended to capture the most recent disease assessment. The most recent…

Q105-130: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen

Comprehensive Disease-Specific Manuals » 2034/2134: X-Linked Lymphoproliferative Sydrome (XLP) » 2034: XLP Pre-HCT » Q105-130: Disease Status at Last Evaluation Prior to the Start of the Preparative Regimen

Question 105: Specify the status of HLH If the patient previously had HLH at any time during their disease course, specify if it was “active” or “inactive” (quiescent) at the last evaluation prior to the start of the preparative regimen. If the patient never…

Q42-130:Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen

Comprehensive Disease-Specific Manuals » 2033/2133: Wiskott-Aldrich Syndome (WAS) » 2033: WAS Pre-HCT » Q42-130:Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen

Infections identified between Diagnosis and the Start of the Preparative Regimen Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. For the purposes of this form, clinically significant…

Q108-127: Clinical Features and Laboratory Studies At Last Evaluation Prior to the Start of the Preparative Regimen

Comprehensive Disease-Specific Manuals » 2039/2139: Hemophagocytic Lymphohistiocytosis (HLH) » 2039: HLH Pre-HCT » Q108-127: Clinical Features and Laboratory Studies At Last Evaluation Prior to the Start of the Preparative Regimen

Question 108: Anemia (Hgb < 9 g/dL): Indicate if the recipient had anemia at the last evaluation prior to the start of the preparative regimen. Anemia is defined as hemoglobin less than 9 g/dL. Select “yes,” “no,” or “unknown.” Question 109: Degranulation…

2553: VOD/SOS

Infection & Miscellaneous Manuals » 2553: VOD/SOS

The Veno-occlusive Disease (VOD) / Sinusoidal Obstruction Syndrome (SOS) Form, Form 2553, must be completed when VOD / SOS has been reported to have developed on the 100 Day Post-HCT Data Form (F2100) or the 100 Day Post-TED Form (Form 2450). Additionally, a Six Month…

Q83-88: Data from Post-HSCT Follow-Up Form (2100)

Infection & Miscellaneous Manuals » 2540: Tepadina® Supplemental Data » Q83-88: Data from Post-HSCT Follow-Up Form (2100)

Questions 83-88 refer to data reported on form 2100, Q441-615, please ensure data reported here matches with form 2100. Questions 83-85: In the transplant physician’s judgment, were any of the disorders / impairments reported on the form 2100 a direct result of…

Q36-82: Organ Function

Infection & Miscellaneous Manuals » 2540: Tepadina® Supplemental Data » Q36-82: Organ Function

Questions 36 – 82: Organ Function This section of the form compliments the organ function section of the Post-HCT Follow Up Data Form, F2100. Hypersensitivity !Questions 36-40 can only be complete on the 100 day follow-up form. These questions will be skipped…

2450: Post-TED

Transplant Essential Data (TED) Manuals » 2450: Post-TED

Transplant centers participating in the CIBMTR must submit a Post-TED Form for recipients who meet any of the following criteria: Recipient receives a transplant at a United States center designated as a TED-only center. Recipient receives a transplant at a United…

2039: HLH Pre-HCT

Comprehensive Disease-Specific Manuals » 2039/2139: Hemophagocytic Lymphohistiocytosis (HLH) » 2039: HLH Pre-HCT

The Hemophagocytic Lymphohistiocytosis Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures HLH-specific Pre-HCT data such as the disease assessment, clinical and laboratory features at diagnosis, history of infection, pre-transplant therapy,…

2011/2111: Acute Lymphoblastic Leukemia (ALL)

Comprehensive Disease-Specific Manuals » 2011/2111: Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia (ALL) is a cancer of the white blood cells. It is characterized by the rapid proliferation of abnormal, immature lymphocytes, or lymphoblasts, in the bone marrow. This accumulation of blasts in the marrow prevents the formation of healthy…

2033: WAS Pre-HCT

Comprehensive Disease-Specific Manuals » 2033/2133: Wiskott-Aldrich Syndome (WAS) » 2033: WAS Pre-HCT

The Wiskott-Aldrich Syndrome Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures WAS-specific pre-HCT data such as: the recipient’s clinical and genetic findings at the time of diagnosis and prior to the start of the preparative regimen,…

Q125-156: POEMS Syndrome Assessment at Diagnosis

Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2016: PCD Pre-Infusion » Q125-156: POEMS Syndrome Assessment at Diagnosis

!Complete questions 125-156 for POEMS patients only. If POEMS was not reported as the primary disease for transplant (question 1) or as a preceding / concurrent disorder (question 2), skip to question 157. Questions 125-126: Specify POEMS clinical features (check all…

2034: XLP Pre-HCT

Comprehensive Disease-Specific Manuals » 2034/2134: X-Linked Lymphoproliferative Sydrome (XLP) » 2034: XLP Pre-HCT

The X-Linked Lymphoproliferative Syndrome Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures XLP-specific pre-HCT data such as: the recipient’s clinical and genetic findings at the time of diagnosis and prior to the start of the…

Q110-141: POEMS Syndrome Assessment at the Time of Best Response

Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2116: PCD Post-Infusion » Q110-141: POEMS Syndrome Assessment at the Time of Best Response

!Complete questions 110-141 for POEMS patients only. If POEMS was not reported as the primary disease for transplant (question 1) or as a preceding / concurrent disorder (question 2), skip to question 142. The response time for POEMS tends to occur well after…

Q121-150: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen

Comprehensive Disease-Specific Manuals » 2019/2119: Waldenström’s Macroglobulinemia (WM) » 2019: WM Pre-HCT » Q121-150: Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen

These questions are intended to determine the status of the recipient prior to the preparative regimen. Testing may be performed multiple times within the pre-transplant workup period (approximately 30 days) prior to the start of the preparative regimen; report the…

Q82-156: Pre-HCT / Pre-Infusion Therapy

Comprehensive Disease-Specific Manuals » 2014/2114: Myelodysplastic Syndrome (MDS) » 2014: Myelodyplastic Syndrome (MDS) Pre-Infusion » Q82-156: Pre-HCT / Pre-Infusion Therapy

The FormsNet3SM application allows questions 83-157 to be reported multiple times. Complete these questions for each line of therapy administered on or after the date of diagnosis of MDS and prior to the start of the preparative regimen (or prior to infusion if no…

Q104-144: Disease Status at the Time of Evaluation for This Reporting Period

Comprehensive Disease-Specific Manuals » 2010/2110: Acute Myelogenous Leukemia (AML) » 2110: AML Post-Infusion » Q104-144: Disease Status at the Time of Evaluation for This Reporting Period

Question 104: Does the current disease status reflect the disease detected in this reporting period section (as captured in questions 51-89), without subsequent therapy? This section of the form is intended to capture the most recent disease assessment. The most…

2100: Post-Infusion Follow-Up

Comprehensive Baseline & Follow-up Manuals » 2100: Post-Infusion Follow-Up

A transplant center designated as a Comprehensive Report Form center will submit data on the Pre-TED and Pre-TED Disease Classification Forms, followed by either the Post-TED Form or the Comprehensive Report Forms. The type of follow-up forms required for a specific…

Q1-28: Diagnosis

Infection & Miscellaneous Manuals » 2553: VOD/SOS » Q1-28: Diagnosis

Veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) may occur have HCT as a conditioning regimen injury to the hepatic venous endothelium, resulting in hepatic venous outflow obstruction due to occlusion of the hepatic venules and sinusoids. This…

2111: ALL Post-Infusion

Comprehensive Disease-Specific Manuals » 2011/2111: Acute Lymphoblastic Leukemia (ALL) » 2111: ALL Post-Infusion

The Acute Lymphoblastic Leukemia Post-Infusion Data Form (Form 2111) is one of the Comprehensive Report Forms. This form captures ALL-specific post-infusion data such as: the recipient’s best response to HCT or cellular therapy, cytogenetic and molecular findings at…

Q121 – 135: Pre-HCT Preparative Regimen (Conditioning)

Transplant Essential Data (TED) Manuals » 2400: Pre-TED » Q121 – 135: Pre-HCT Preparative Regimen (Conditioning)

Question 121 Height at initiation of pre-HCT preparative regimen Report the recipient’s height just prior to the start of the preparative regimen. The intent of this question is to determine the height used when calculating preparative regimen drug doses. This…

Q96-163: Acute Lymphoblastic Leukemia

Transplant Essential Data (TED) Manuals » 2402: Disease Classification » Q96-163: Acute Lymphoblastic Leukemia

!Acute Lymphoblastic Lymphoma Due to the aggressive nature of precursor T- and precursor B-cell lymphoblastic lymphoma (or lymphoma / leukemia), the primary disease reported for recipients with these malignancies should be acute lymphoblastic leukemia (T-cell…

Q1 – 159: Disease Assessments at Time of Best Response to HSCT

Comprehensive Disease-Specific Manuals » 2026/2126: Neuroblastoma » 2126: Neuroblastoma Post-Infusion » Q1 – 159: Disease Assessments at Time of Best Response to HSCT

Question 1: Compared to the disease status prior to the preparative regimen what was the best response since the date of the last report? (Include response to any post-HSCT treatment planned as of day 0) The intent of this question is to determine the best overall…

2019 Manual Updates

Getting Started » Historical Manual Updates » 2019 Manual Updates

January 2019 February 2019 March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 October 2019 December 2019 Updates made during the current calendar year are included below. For updates prior to 2019, click on the subtopic corresponding to the year of…

2017 Manual Updates

Getting Started » Historical Manual Updates » 2017 Manual Updates

December 2017 November 2017 October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 !Hyperlinks Please note, hyperlinks on this page will not work for any manual sections which have been retired and / or…

2020 Manual Updates

Getting Started » Historical Manual Updates » 2020 Manual Updates

January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 October 2020 December 2020 Updates made during the current calendar year are included below. For updates prior to 2020, click on the subtopic corresponding to the year of…

Q105-202: Disease Detection Since the Date of Last Report

Comprehensive Disease-Specific Manuals » 2057/2157 Myeloproliferative Neoplasms (MPN) » 2157: Myeloproliferative Neoplasm (MPN) Post-Infusion » Q105-202: Disease Detection Since the Date of Last Report

Questions 105-106: Did the recipient have splenomegaly? Indicate if the recipient had splenomegaly indicative of disease detection since the date of the last report. Splenomegaly is often documented during the physician’s physical assessment of the recipient and…

Q88-171: Most Recent Laboratory Studies

Comprehensive Disease-Specific Manuals » 2014/2114: Myelodysplastic Syndrome (MDS) » 2114: Myelodysplastic Syndrome (MDS) Post-Infusion » Q88-171: Most Recent Laboratory Studies

!Questions 88-99 refer to overlap syndromes including CMMoL; JMML; aCML; MDS/MPN-RS-T; MDS/MPN, unclassifiable; if the diagnosis was other than an overlap syndrome, continue with question 100. Questions 88-89: Did the recipient have splenomegaly? Indicate if the…

Q110-194: Post-HCT / Post-Infusion Therapy

Comprehensive Disease-Specific Manuals » 2012/2112: Chronic Myeloid Leukemia (CML) » 2112: CML Post-Infusion Data » Q110-194: Post-HCT / Post-Infusion Therapy

*Therapy for Persistent Disease Report treatment for persistent disease (excluding MRD) in questions 110-132. Do not include therapy which has already been reported in questions 64-99 (planned therapy including maintenance and consolidation) unless the treatment is…

Q1 – 141: Disease Assessment at Diagnosis

Comprehensive Disease-Specific Manuals » 2029/2129: Fanconi Anemia / Constitutional Anemia » 2029: Fanconi Anemia / Constitutional Anemia Pre-HCT » Q1 – 141: Disease Assessment at Diagnosis

Question 1: What was the date of diagnosis of Fanconi Anemia? Report the date of first pathological evaluation (e.g., bone marrow biopsy) or blood/serum assessment (e.g., CBC, peripheral blood smear) that determined the diagnosis of Fanconi anemia. Enter the date the…

Q80-170: Toxicities

Cellular Therapy Manuals » 4100: Cellular Therapy Essential Data Follow-Up » Q80-170: Toxicities

*Report any observed toxicity or infection that occurs post-infusion in this reporting period, regardless of causality and whether or not treatment was administered. The intent is to capture all toxicities diagnosed after the cellular therapy infusion. Although…